Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sapporo Clinical Laboratory (TSE:9776) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Sapporo Clinical Laboratory Return-on-Tangible-Asset Related Terms
Sapporo Clinical Laboratory Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sapporo Clinical Laboratory Return-on-Tangible-Asset Chart
Sapporo Clinical Laboratory Return-on-Tangible-Asset Competitor Comparison
For the Pharmaceutical Retailers subindustry, Sapporo Clinical Laboratory's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sapporo Clinical Laboratory Return-on-Tangible-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sapporo Clinical Laboratory's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Sapporo Clinical Laboratory's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Sep. 2025) net income data.
What does a Return-on-Tangible-Asset of 3.04% mean?
Sapporo Clinical Laboratory (TSE:9776) has a Return-on-Tangible-Asset of 3.04% as of Sep. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Sapporo Clinical Laboratory and its competitors. This is 41% below median its historical median of 5.17. Over the past decade, Sapporo Clinical Laboratory's Return-on-Tangible-Asset has ranged from 2.30 to 6.83.
Is Sapporo Clinical Laboratory's Return-on-Tangible-Asset too high?
Sapporo Clinical Laboratory's current Return-on-Tangible-Asset of 3.04% is 41% below median its 10-year median of 5.17. Over the past 10 years, this metric has ranged from a low of 2.30 to a high of 6.83. The Healthcare Providers & Services industry median Return-on-Tangible-Asset is 2.61. Sapporo Clinical Laboratory's value of 3.04% is 16.7% above this industry median. Overall, Sapporo Clinical Laboratory has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Sapporo Clinical Laboratory's Return-on-Tangible-Asset compare to competitors?
Sapporo Clinical Laboratory's Return-on-Tangible-Asset of 3.04% can be compared against companies in the Healthcare Providers & Services industry. The industry median Return-on-Tangible-Asset is 2.61. Sapporo Clinical Laboratory's value of 3.04% is 16.7% above this benchmark. Historically, Sapporo Clinical Laboratory's own Return-on-Tangible-Asset has ranged from 2.30 to 6.83 over the past decade. While the company's 10-year median is 5.17 vs. the industry median of 2.61, Sapporo Clinical Laboratory has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Healthcare Providers & Services company?
The median Return-on-Tangible-Asset among Healthcare Providers & Services companies is 2.61, based on 680 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sapporo Clinical Laboratory's current Return-on-Tangible-Asset of 3.04% is 16.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Sapporo Clinical Laboratory and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Asset is 2.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sapporo Clinical Laboratory's current Return-on-Tangible-Asset is 3.04%, which is 41% below median its own 10-year median of 5.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sapporo Clinical Laboratory stock overvalued right now?
Sapporo Clinical Laboratory (TSE:9776) has a current Return-on-Tangible-Asset of 3.04%. The stock's GF Value™ is 円1,041.47, compared to a current price of 円1,960.00 — trading 88.2% above its estimated fair value. The current Return-on-Tangible-Asset is 3.04%, which is 41% below median its 10-year median of 5.17 and 16.7% above the Healthcare Providers & Services industry median of 2.61. Sapporo Clinical Laboratory's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Sapporo Clinical Laboratory (TSE:9776), the current Return-on-Tangible-Asset is 3.04% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sapporo Clinical Laboratory (TSE:9776) Overvalued in 2026?
Based on GuruFocus' analysis, Sapporo Clinical Laboratory stock appears to be overvalued.
The current stock price of 円1,960.00 is trading 88.2% above its estimated GF Value™ of 円1,041.47.
Key valuation signals for TSE:9776:
Return-on-Tangible-Asset: 3.04% (41% below median its 10-year median of 5.17)
GF Value™: 円1,041.47 vs. price of 円1,960.00 (88.2% above fair value)
Industry Position: 16.7% above the Healthcare Providers & Services median
No single metric tells the full story. See the TSE:9776 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sapporo Clinical Laboratory Inc. is a Japan based company engaged in offering clinical testing services. Its portfolio of services covers clinical examination, pathological examination, dispensing pharmacy, food hygiene environmental test, and radiation management. It is also engaged in the development of an integrated system for clinical testing.
43GF Score
Get the complete analysis for TSE:9776
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:9776 has been successfully added to your 
